Melvin J B, Haight T H, Leduc E H
Cancer Res. 1984 Jul;44(7):2794-8.
The effects of 50% lethal doses of three purine analogues, 6-methylmercaptopurine riboside ( MMPR ), 6-thioguanosine (TGR), and 6- selenoguanosine ( SeGR ), on mitotic activity in a slow-growing ( SS1H ) and a fast-growing ( BH3 ) transplantable hepatocellular adenoma in C3H/ StW and BUB mice, respectively, were analyzed statistically. No significant difference in response was found between the two benign hepatomas. MMPR alone effectively reduced mitotic activity in the tumors and did so as efficiently on the first day of treatment as on subsequent days of daily i.p. administrations for up to 10 days. TGR alone and SeGR alone were ineffective in reducing the mitotic index significantly below that of controls. When either TGR or SeGR was injected simultaneously with MMPR , the effect on tumor mitosis resembled that of MMPR alone. The reactions of normal cells of the hosts to these agents were analyzed quantitatively in duodenal epithelium with respect to mitotic activity and to the number of cells present in the crypts. Differences between the two strains of mice were small and, for the most part, not significant. MMPR produced a slight but not significant reduction in duodenal mitotic activity and cell number. TGR alone induced significant decreases in both after 3 and 5 days of treatment. SeGR alone had no effect on the duodena . The effects of a combination of SeGR with MMPR on the duodena differed only slightly from MMPR or SeGR alone, but TGR plus MMPR produced greater inhibition of mitosis than did either administered alone. Our results suggest that MMPR may be a promising chemotherapeutic agent against some types of solid hepatocellular tumors in vivo because it can inhibit mitosis in these tumors effectively, rapidly, and continuously, while its inhibitory effect on normal replicating cells of the host intestine occurs more slowly and only with long-sustained treatment.
分别分析了三种嘌呤类似物50%致死剂量,即6-甲基巯基嘌呤核苷(MMPR)、6-硫代鸟苷(TGR)和6-硒代鸟苷(SeGR)对C3H/StW小鼠体内生长缓慢的(SS1H)和BUB小鼠体内生长快速的(BH3)可移植性肝细胞腺瘤有丝分裂活性的影响。在这两种良性肝肿瘤之间未发现反应上的显著差异。单独使用MMPR可有效降低肿瘤中的有丝分裂活性,且在治疗第一天的效果与随后连续10天每天腹腔注射给药时的效果一样显著。单独使用TGR和单独使用SeGR均不能将有丝分裂指数显著降低至低于对照组。当TGR或SeGR与MMPR同时注射时,对肿瘤有丝分裂的影响与单独使用MMPR时相似。在十二指肠上皮中,就有丝分裂活性和隐窝中细胞数量而言,对宿主正常细胞对这些药物的反应进行了定量分析。两种小鼠品系之间的差异很小,且在大多数情况下不显著。MMPR使十二指肠有丝分裂活性和细胞数量略有降低,但不显著。单独使用TGR在治疗3天和5天后均导致二者显著降低。单独使用SeGR对十二指肠无影响。SeGR与MMPR联合使用对十二指肠的影响与单独使用MMPR或SeGR仅略有不同,但TGR加MMPR比单独使用二者对有丝分裂的抑制作用更强。我们的结果表明,MMPR可能是一种有前景的体内抗某些类型实体肝细胞肿瘤的化疗药物,因为它可以有效、快速且持续地抑制这些肿瘤中的有丝分裂,而其对宿主肠道正常复制细胞的抑制作用出现得更慢,且仅在长期持续治疗时才会出现。